Big tech- and pharma-backed Iambic Therapeutics aims for $135m IPO - Pharmaceutical Technology

A US listing for the oncology specialist continues a bumper year for biotech IPOs. A US listing for the oncology specialist continues a bumper year for biotech IPOs. The biotech is listing on the Nasdaq Global Select Market under the symbol “IAM”. Credit: Piotr Swat/Shutterstock.com. Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical development of its AI-powered oncology pipeline. Adding financial flavour to its initial listing plans announced last month, Iambic is offering 9.4 million shares…

Source: Pharmaceutical Technology